Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?

Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19. The hype surrounding the potential for Nuvaxovid drove Novavax shares as high as $331.68 in February 2021. However, the reality of missteps resulting in being "late to the party" caused shares to crater to$3.53 by February 2024. Shares have since surged as high as $23.86 in June 2024 on a$1.2 billion licensin ...